Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 11/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GLP1R | P43220 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1917659 | 1.00 | CYP1A2 (0.46) | CYP1A2CYP3A4HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL3310812 | 0.83 | STK17B (0.57) | CYP1A2CYP3A4HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL1916915 | 0.82 | CYP3A4 (0.48) | CYP1A2CYP3A4HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL2816596 | 0.81 | GLP1R (0.45) | CYP1A2CYP3A4HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL1774178 | 0.81 | GLP1R (0.45) | CYP1A2CYP3A4HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL13177678 | 0.81 | GLP1R (0.45) | CYP1A2CYP3A4HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL3287052 | 0.80 | GLP1R (0.44) | CYP1A2CYP3A4HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL1916465 | 0.80 | GLP1R (0.44) | CYP1A2CYP3A4HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL13360542 | 0.78 | GLP1R (0.43) | CYP1A2CYP3A4HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL1917420 | 0.78 | GLP1R (0.46) | CYP1A2CYP3A4HSD17B10ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | disclosed |
| EP-1438053-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-21 | — | — | EP | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
| WO-2003032997-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | CYP1A2 224/4885CYP3A4 885/4885HSD17B10 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.